LEO Pharma’s delgocitinib hits main goals in moderate-to-severe chronic hand eczema
pharmafile | November 2, 2020 | News story | Research and Development, Sales and Marketing | LEO Pharma, eczema, pharma
LEO Pharma has revealed new Phase 2b at the European Academy of Dermatology and Venereology (EADV) Virtual 2020 Virtual Congress supporting the efficacy of its pan-Janus kinase (JAK)-inhibitor delgocitinib in the treatment of mild-to-severe chronic hand eczema (CHE).
The company announced that the topical cream met its primary and secondary endpoints in the study.
Data drawn from the trial demonstrated that a clinically significant percentage of CHE patients was shown to have achieved an Investigator’s Global Assessment (IGA)-CHE score of 0 or 1, representing clear or almost clear skin, with an improvement of at least two points from baseline 16 weeks after receiving initial dosing.
Delgocitinib also generated a positive change from baseline in patients according to the Hand Eczema Severity Index (HECSI) at week 16, hitting the study’s secondary endpoint.
“There is considerable unmet need for treatments to help individuals with chronic hand eczema, known as CHE, to manage their condition long term. CHE causes significant burden on people’s lives; impacting self-esteem and ability to do work,” said Amit Aggarwal, Medical Director at LEO Pharma’s North Europe, Australia & New Zealand cluster. “It is positive to see that the results of this trial suggest that delgocitinib cream could become a future treatment option for patients suffering from mild-to-severe CHE.”
Delgocitinib hasn’t yet secured regulatory approval from any regulator worldwide, but was awarded Fast Track designation for moderate-to-severe CHE from the FDA earlier this year.
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition
LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe …
